ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION
Martin J. van den Bent(Erasmus MC Cancer Institute), Pim J. French(Erasmus MC Cancer Institute), Warren Mason(Princess Margaret Cancer Centre), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), ken aldape, Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Sara Erridge(The University of Texas MD Anderson Cancer Center), Mircea Tesileanu(Erasmus MC Cancer Institute), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Brigitta G. Baumert(Kantonsspital Graubünden), Helen Wheeler(The University of Sydney), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum(Moffitt Cancer Center), Jean-Francais Baurain(Cliniques Universitaires Saint-Luc)
Cited by 6
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k